Veradermics (NYSE:MANE) Releases Earnings Results

Veradermics (NYSE:MANE) issued its quarterly earnings data on Tuesday. The company reported ($0.50) EPS for the quarter, FiscalAI reports.

Veradermics Stock Performance

Veradermics stock traded up $5.22 during mid-day trading on Tuesday, hitting $149.17. 261,574 shares of the company traded hands, compared to its average volume of 639,709. Veradermics has a one year low of $32.00 and a one year high of $152.82. The stock has a market cap of $6.23 billion and a price-to-earnings ratio of -78.05. The stock has a fifty day moving average price of $118.66 and a 200-day moving average price of $97.43.

Insider Activity at Veradermics

In other news, insider Timothy August Durso sold 43,500 shares of Veradermics stock in a transaction on Monday, August 17th. The shares were sold at an average price of $107.82, for a total transaction of $4,690,170.00. Following the completion of the sale, the insider directly owned 78,142 shares of the company’s stock, valued at approximately $8,425,270.44. The trade was a 35.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Reid Alexander Waldman sold 67,500 shares of Veradermics stock in a transaction on Monday, August 17th. The stock was sold at an average price of $107.86, for a total transaction of $7,280,550.00. Following the sale, the chief executive officer directly owned 170,824 shares of the company’s stock, valued at $18,425,076.64. This represents a 28.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 961,000 shares of company stock worth $103,120,220 over the last quarter.

Institutional Investors Weigh In On Veradermics

A number of large investors have recently added to or reduced their stakes in MANE. Nvwm LLC raised its holdings in shares of Veradermics by 105.4% during the 3rd quarter. Nvwm LLC now owns 228 shares of the company’s stock valued at $28,000 after buying an additional 117 shares in the last quarter. Sterling Capital Management LLC boosted its stake in Veradermics by 233.2% in the third quarter. Sterling Capital Management LLC now owns 633 shares of the company’s stock worth $77,000 after buying an additional 443 shares in the last quarter. Russell Investments Group Ltd. grew its position in Veradermics by 8.4% during the third quarter. Russell Investments Group Ltd. now owns 1,905 shares of the company’s stock valued at $231,000 after acquiring an additional 147 shares during the last quarter. Pictet Asset Management Holding SA grew its position in Veradermics by 22.0% during the third quarter. Pictet Asset Management Holding SA now owns 2,491 shares of the company’s stock valued at $302,000 after acquiring an additional 449 shares during the last quarter. Finally, Arizona State Retirement System purchased a new position in shares of Veradermics during the second quarter worth approximately $524,000.

Analyst Upgrades and Downgrades

Several research analysts have commented on MANE shares. UBS Group set a $204.00 price target on shares of Veradermics in a report on Thursday, October 22nd. Needham & Company LLC upped their price target on shares of Veradermics from $164.00 to $172.00 and gave the stock a “buy” rating in a report on Monday, October 19th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Veradermics in a research report on Friday, August 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Veradermics in a research note on Monday, October 19th. Finally, Wall Street Zen upgraded Veradermics from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $172.43.

Key Stories Impacting Veradermics

Here are the key news stories impacting Veradermics this week:

• Positive Sentiment: Veradermics reported positive 12-month results from Part B of Phase 3 Study 302 in men with pattern hair loss. The company said the study produced the highest hair-count result reported to date in its VDPHL01 Phase 3 program, strengthening the candidate’s potential and supporting investor optimism. Article: Veradermics Achieved the Highest VDPHL01 Reported Hair Count
• Positive Sentiment: Leerink Partners raised its price target from $135 to $150 and maintained an Outperform rating, adding analyst support after the clinical update. Article: Leerink Partners recommendations
• Neutral Sentiment: The company reported a third-quarter loss of $0.50 per share. The available report did not provide an analyst-forecast comparison, so the result’s significance versus expectations is unclear. Article: Veradermics Reports Third Quarter 2026 Results

Veradermics Company Profile

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.